The efficacy of bevacizumab in combination with erlotinib or afatinib for the treatment of untreated advanced EGFR-mutated lung adenocarcinoma has been explored in several previous pivotal clinical trials and clinical studies (13–17). The gene discussed is EGFR; the disease is lung adenocarcinoma.